Clinical/Research Interests

Specialty:

Center/Program Affiliation:

Address:

Phone:

Education:

Internships:

Residency:

Fellowships:

Board Certifications:

Professional Memberships:

Select Recent Publications:

Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) inpatients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol.3(9):1026-31, 2008.

Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 14(17):5565-70, 2008.

Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26(29):4771-6. 2008.

Gandara DR, Lara PN Jr, Natale R, Belani C.Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol.26(26):4236-8, 2008.

Xiao GG, Zhou BS, Somlo G, Portnow J, Juhasz A, Un F, Chew H, Gandara D, Yen Y. Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy. Cancer Genomics Proteomics. 5(3-4):151-60, 2008.

McGill C, Gandara DR. Highlights from: The Addario Lung Cancer Medical Institute Summit.Clin Lung Cancer. 2008 Sep;9(5):254-6, 2008

Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 3(1):68-74, 2008.

Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara DR, Davis SW, Wun T, Chen MS Jr., Lara PN Jr. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer 112(1):212-9, 2008.

Garcia AA, Hirte H, Fleming G, Yang DY, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara DR, Scudder S, Morgan R, Chen H, Lenz H-J, Oza AM. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital Phase II Consortia. JCO 26(1):76-82, 2008.

Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early stage non-small-cell lung cancer. Clin Lung Cancer 9(1):9-15, 2008.